You are here

Approvals, Launches, and New Indications

New combo is a maintenance treatment for virologically suppressed HIV-1
Needle length and dose target patients weighing 16.5 to 33 pounds
Patients can avoid long drives to distant specialists
In study, progression-free survival was superior to Rituxan-based therapy
This is the first new medicine for this population in two decades
First agency-approved treatment for pediatric and adult patients with MPS VII
FDA clears NSS-2 Bridge in an effort to reduce symptoms
New indication marks first adjuvant treatment after nephrectomy
First respiratory biologic with an eight-week maintenance dosing schedule
NK1 receptor antagonist helps with moderately and highly emetogenic chemotherapies